Literature DB >> 11919423

Surrogate markers of disease in mastocytosis.

Cem Akin1, Dean D Metcalfe.   

Abstract

Measurement of surrogate mast cell-related products in blood or urine is often performed to assess disease extent in evaluating patients with mastocytosis. Serum tryptase and 24-hour urine histamine metabolites are the most commonly used surrogate markers of mastocytosis. In addition, several novel markers including soluble CD117 and soluble CD25 have been identified in recent studies. The utility and the pitfalls of each of these measurements are discussed. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11919423     DOI： 10.1159/000048184

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN： 1018-2438            Impact factor:   2.749


  8 in total

Review 1.  [Mast cell activation syndrome].

Authors:  K Brockow
Journal:  Hautarzt       Date:  2013-02       Impact factor: 0.751

Review 2.  Anesthetic considerations in pediatric mastocytosis: a review.

Authors:  Norma J Klein; Shad Misseldine
Journal:  J Anesth       Date:  2013-02-14       Impact factor: 2.078

3.  Elevation in histamine and tryptase following exercise in patients with mastocytosis.

Authors:  Joseph M Kulinski; Dean D Metcalfe; Michael L Young; Yun Bai; Yuzhi Yin; Robin Eisch; Linda M Scott; Hirsh D Komarow
Journal:  J Allergy Clin Immunol Pract       Date:  2018-07-23

4.  Clinical correlates of blood serotonin levels in patients with mastocytosis.

Authors:  N M Kushnir-Sukhov; E Brittain; L Scott; D D Metcalfe
Journal:  Eur J Clin Invest       Date:  2008-12       Impact factor: 4.686

5.  Determination of plasma heparin level improves identification of systemic mast cell activation disease.

Authors:  Milda Vysniauskaite; Hans-Jörg Hertfelder; Johannes Oldenburg; Peter Dreßen; Stefan Brettner; Jürgen Homann; Gerhard J Molderings
Journal:  PLoS One       Date:  2015-04-24       Impact factor: 3.240

6.  Osteoporosis and osteopathy markers in patients with mastocytosis.

Authors:  Nilüfer Alpay Kanıtez; Burak Erer; Öner Doğan; Nesimi Büyükbabani; Can Baykal; Dilşad Sindel; Refik Tanakol; Akif Selim Yavuz
Journal:  Turk J Haematol       Date:  2015-03-05       Impact factor: 1.831

7.  Altered Metabolism of Phospholipases, Diacylglycerols, Endocannabinoids, and N-Acylethanolamines in Patients with Mastocytosis.

Authors:  Anne Lise Ferrara; Fabiana Piscitelli; Angelica Petraroli; Roberta Parente; Maria Rosaria Galdiero; Gilda Varricchi; Giancarlo Marone; Massimo Triggiani; Vincenzo Di Marzo; Stefania Loffredo
Journal:  J Immunol Res       Date:  2019-07-01       Impact factor: 4.818

8.  Hereditary α tryptasemia is a valid genetic biomarker for severe mediator-related symptoms in mastocytosis.

Authors:  Georg Greiner; Bettina Sprinzl; Aleksandra Górska; Franz Ratzinger; Michael Gurbisz; Nadine Witzeneder; Klaus G Schmetterer; Bettina Gisslinger; Goekhan Uyanik; Emir Hadzijusufovic; Harald Esterbauer; Karoline V Gleixner; Maria T Krauth; Michael Pfeilstöcker; Felix Keil; Heinz Gisslinger; Boguslaw Nedoszytko; Marek Niedoszytko; Wolfgang R Sperr; Peter Valent; Gregor Hoermann
Journal:  Blood       Date:  2021-01-14       Impact factor: 22.113
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.